Janes MR - Search Results

1

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.

2

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1. Leukemia. 2013. PMID: 23090679 Free PMC article.

3

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Kharas MG, et al. Among authors: janes mr. J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. J Clin Invest. 2008. PMID: 18704194 Free PMC article.

4

Immune regulation by rapamycin: moving beyond T cells.

Janes MR, Fruman DA. Janes MR, et al. Sci Signal. 2009 Apr 21;2(67):pe25. doi: 10.1126/scisignal.267pe25. Sci Signal. 2009. PMID: 19383976

5

Targeting TOR dependence in cancer.

Janes MR, Fruman DA. Janes MR, et al. Oncotarget. 2010 May;1(1):69-76. doi: 10.18632/oncotarget.110. Oncotarget. 2010. PMID: 20657741 Free PMC article.

6

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA. So L, et al. Among authors: janes mr. J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28. J Biol Chem. 2013. PMID: 23275335 Free PMC article.

7

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Janes MR, Fruman DA. Janes MR, et al. Methods Mol Biol. 2012;821:251-65. doi: 10.1007/978-1-61779-430-8_15. Methods Mol Biol. 2012. PMID: 22125070

8

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. Hsieh AC, et al. Among authors: janes mr. Nature. 2012 Feb 22;485(7396):55-61. doi: 10.1038/nature10912. Nature. 2012. PMID: 22367541 Free PMC article.

9

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Mallya S, et al. Among authors: janes mr. PLoS One. 2014 Feb 21;9(2):e88865. doi: 10.1371/journal.pone.0088865. eCollection 2014. PLoS One. 2014. PMID: 24586420 Free PMC article.

10

B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.

Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B. Casey SC, et al. Among authors: janes mr. Mol Endocrinol. 2011 Jun;25(6):933-43. doi: 10.1210/me.2010-0486. Epub 2011 Mar 24. Mol Endocrinol. 2011. PMID: 21436254 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page